专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006052566A3 GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS 审中-公开
标题翻译： GPR41及其与胰岛素相关性疾病治疗的调节剂
公开(公告)号：WO2006052566A3
公开(公告)日：2006-10-12
申请号：PCT/US2005039551
申请日：2005-11-01
申请人： ARENA PHARM INC , LEONARD JAMES N , CHU ZHI LIANG , BRUCE MARC A , BOATMAN P DOUGLAS
发明人： LEONARD JAMES N , CHU ZHI LIANG , BRUCE MARC A , BOATMAN P DOUGLAS
IPC分类号： A61K49/00 , G01N33/50
CPC分类号： G01N33/66 , G01N2500/04
摘要： The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.
摘要翻译：本发明涉及通过以下方式鉴定血糖稳定化合物的方法：a）使候选化合物与GPR41接触，以及b）确定是否调节GPR41功能性，其中GPR41官能度的调节指示候选化合物是血糖稳定剂复合。此外，本发明涉及一种鉴定血糖稳定化合物的方法，包括：a）使候选化合物与GPR41接触，和b）确定GPR41的功能是否增加，其中GPR41功能的增加指示候选化合物为血糖稳定化合物。此外，本发明涉及用于鉴定血糖稳定化合物的方法，其包括：a）使候选化合物与GPR41接触，和b）确定GPR41的功能性是否降低，其中GPR41官能度的降低指示候选化合物为血糖稳定化合物。

2. 发明申请

WO2005119252A3 MODULATORS OF GPR35 FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 审中-公开
标题翻译： GPR35的调节剂用于治疗与代谢相关的疾病
公开(公告)号：WO2005119252A3
公开(公告)日：2006-01-12
申请号：PCT/US2005018082
申请日：2005-05-23
申请人： ARENA PHARM INC , LEONARD JAMES N , CHU ZHI LIANG , UNETT DAVID J , GATLIN JOEL E , GAIDAROV IBRAGIM , QIU JUN , SKINNER PHILIP J , BOATMAN P DOUGLAS
发明人： LEONARD JAMES N , CHU ZHI LIANG , UNETT DAVID J , GATLIN JOEL E , GAIDAROV IBRAGIM , QIU JUN , SKINNER PHILIP J , BOATMAN P DOUGLAS
IPC分类号： A61K31/425 , G01N33/50 , A61P3/06 , A61P3/10
CPC分类号： G01N33/6893 , A61K31/425 , G01N2333/726 , G01N2500/00
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR35, and b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates to use of a GPR35 modulator for the manufacture of a medicament for use as a metabolic stabilizing agent. In addition, the invention relates to a method for increasing GPR35 function, comprising contacting GPR35 with an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X is O or S; and R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, C1-4 alkoxy, C1-4 alkyl, halogen, hydroxyl, and nitro; wherein said C1-4 alkoxy is optionally substituted with carbo-C1-4-alkoxy or carboxy.
摘要翻译：本发明涉及用于鉴定代谢稳定化合物的方法，包括：a）使候选化合物与GPR35接触，和b）确定GPR35的功能是否增加，其中GPR35功能的增加指示候选化合物是代谢稳定化合物。本发明还涉及GPR35调节剂在制备用作代谢稳定剂的药物中的用途。另外，本发明涉及增加GPR35功能的方法，其包括使GPR35与有效量的式（I）化合物或其药学上可接受的盐接触，其中X为O或S; 并且R 1，R 2，R 3，R 4和R 5各自独立地选自H，C 1-4烷氧基，C 1-4烷基，卤素，羟基和硝基; 其中所述C 1-4烷氧基任选被碳-C 1-4 - 烷氧基或羧基取代。

3. 发明申请

WO2007027225A3 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY AND DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL 审中-公开
标题翻译：联合治疗肥胖和糖尿病的相关治疗以及相关的治疗条件和增加血液GLP-1水平
公开(公告)号：WO2007027225A3
公开(公告)日：2007-11-22
申请号：PCT/US2006016024
申请日：2006-04-26
申请人： ARENA PHARM INC , CHU ZHI-LIANG , LEONARD JAMES N
发明人： CHU ZHI-LIANG , LEONARD JAMES N
IPC分类号： A61K31/40 , A61K31/403 , A61K31/405 , A61K31/4172 , A61K31/426 , A61K31/4439 , A61K31/445 , A61K31/497 , A61K31/4985 , A61K31/513 , A61K38/08 , A61P3/04 , A61P3/10 , A61P9/10 , A61P25/28
CPC分类号： G01N33/6893 , A61K31/40 , A61K31/403 , A61K31/405 , A61K31/4172 , A61K31/426 , A61K31/4439 , A61K31/445 , A61K31/497 , A61K31/4985 , A61K31/513 , A61K38/177 , A61K38/26 , A61K45/06 , C07K14/605 , C07K14/715 , G01N33/567 , G01N2333/726 , G01N2500/04 , G01N2800/042 , A61K2300/00
摘要： The present invention concerns combination of an amount of a BRS-3 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the BRS-3 agonist alone and by the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing obesity and diabetes and conditions related thereto and conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
摘要翻译：本发明涉及一定量的BRS-3激动剂与一定量的二肽基肽酶IV（DPP-IV）抑制剂的组合，使得该组合提供降低血糖水平或增加血液GLP-1水平的作用在超过由单独BRS-3激动剂的量和仅由DPP-IV抑制剂的量提供的受试者中，以及这种组合用于治疗或预防肥胖症和糖尿病及其相关病症和通过增加血液GLP-1水平。本发明还涉及G蛋白偶联受体用于筛选GLP-1促分泌素的用途。

4. 发明申请

WO2007120689A2 METHODS OF USING GPR119 RECEPTOR TO IDENTIFY COMPOUNDS USEFUL FOR INCREASING BONE MASS IN AN INDIVIDUAL 审中-公开
标题翻译：使用GPR119受体鉴定化合物有助于增加个体骨质量的方法
公开(公告)号：WO2007120689A2
公开(公告)日：2007-10-25
申请号：PCT/US2007008902
申请日：2007-04-10
申请人： ARENA PHARM INC , CHU ZHI-LIANG , LEONARD JAMES N
发明人： CHU ZHI-LIANG , LEONARD JAMES N
IPC分类号： C12Q1/68
CPC分类号： G01N33/74 , G01N33/5005 , G01N2333/726 , G01N2800/108
摘要： The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
摘要翻译：本发明涉及使用GPR119受体鉴定可用于增加个体骨量的化合物的方法。 GPR119受体的激动剂可用作治疗或预防以低骨量为特征的疾病如骨质疏松症和用于增加个体骨量的治疗剂。 GPR119受体的激动剂促进个体的骨形成。

5. 发明申请

WO2007120702A3 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO 审中-公开
标题翻译：使用GPR119受体激素增加骨质量和治疗骨质疏松症，以及与之相关的组合治疗
公开(公告)号：WO2007120702A3
公开(公告)日：2008-05-22
申请号：PCT/US2007008926
申请日：2007-04-10
申请人： ARENA PHARM INC , CHU ZHI-LIANG , LEONARD JAMES N , LEHMANN JUERG , JONES ROBERT M
发明人： CHU ZHI-LIANG , LEONARD JAMES N , LEHMANN JUERG , JONES ROBERT M
IPC分类号： A61K31/00 , A61K31/4375 , A61K31/4439 , A61K31/4545 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/522 , A61K45/06 , A61P19/02 , A61P19/08 , A61P19/10
CPC分类号： A61K31/00 , A61K31/4375 , A61K31/4439 , A61K31/4545 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/522 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
摘要翻译：本发明涉及GPR119受体激动剂用于治疗或预防以低骨量为特征的疾病，例如骨质疏松症，以及增加个体骨量。本发明还涉及GPR119受体激动剂与二肽基肽酶IV（DPP-IV）抑制剂组合用于治疗或预防以低骨量为特征的疾病如骨质疏松症以及增加个体中的骨量的用途。 GPR119受体激动剂和GPR119受体激动剂和DPP-IV抑制剂的组合促进个体中的骨形成。

6. 发明申请

WO2006076231A8 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL 审中-公开
标题翻译：治疗与之相关的糖尿病和病症以及通过增加血液GLP-1水平来治疗条件的组合治疗
公开(公告)号：WO2006076231A8
公开(公告)日：2006-09-21
申请号：PCT/US2006000510
申请日：2006-01-09
申请人： ARENA PHARM INC , CHU ZHI-LIANG , LEONARD JAMES N , AL-SHAMMA HUSSIEN A , JONES ROBERT M
发明人： CHU ZHI-LIANG , LEONARD JAMES N , AL-SHAMMA HUSSIEN A , JONES ROBERT M
IPC分类号： A61K31/00 , A61K31/401 , A61K31/4196 , A61P3/10
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
摘要翻译：本发明涉及一定量的GPR119激动剂与二肽基肽酶IV（DPP-IV）抑制剂的量的组合，使得该组合提供降低血糖水平或增加血液GLP-1水平的效果受限于GPR119激动剂的量或单独的DPP-IV抑制剂的量以及这样的组合用于治疗或预防糖尿病和与之相关的病症或通过增加血液GLP-1水平而改善的病症。本发明还涉及G蛋白偶联受体筛选GLP-1促分泌素的用途。

7. 发明申请

WO2006076231A3 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL 审中-公开
标题翻译：治疗与之相关的糖尿病和病症以及通过增加血液GLP-1水平来治疗条件的组合治疗
公开(公告)号：WO2006076231A3
公开(公告)日：2007-01-18
申请号：PCT/US2006000510
申请日：2006-01-09
申请人： ARENA PHARM INC , CHU ZHI-LIANG , LEONARD JAMES N , AL-SHAMMA HUSSIEN A , JONES ROBERT M
发明人： CHU ZHI-LIANG , LEONARD JAMES N , AL-SHAMMA HUSSIEN A , JONES ROBERT M
IPC分类号： A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61P3/00 , A61P3/10 , C12N15/12 , G01N33/566 , G01N33/58
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
摘要翻译：本发明涉及一定量的GPR119激动剂与二肽基肽酶IV（DPP-IV）抑制剂的量的组合，使得该组合提供降低血糖水平或增加血液GLP-1水平的效果受限于GPR119激动剂的量或单独的DPP-IV抑制剂的量以及这样的组合用于治疗或预防糖尿病和与之相关的病症或通过增加血液GLP-1水平而改善的病症。本发明还涉及G蛋白偶联受体筛选GLP-1促分泌素的用途。

8. 发明申请

WO2006036688A2 GPR43 AND MODULATORS THEREOF FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 审中-公开
标题翻译： GPR43及其调节剂用于治疗与代谢相关的病症
公开(公告)号：WO2006036688A2
公开(公告)日：2006-04-06
申请号：PCT/US2005033795
申请日：2005-09-21
申请人： ARENA PHARM INC , LEONARD JAMES N , HAKAK YARON
发明人： LEONARD JAMES N , HAKAK YARON
CPC分类号： G01N33/566 , G01N33/6845 , G01N2333/726 , G01N2500/00
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.
摘要翻译：本发明涉及通过以下步骤鉴定代谢稳定化合物的方法：a）使候选化合物与GPR43接触，和b）确定GPR43功能性是否被调节，其中GPR43功能性的调节指示候选化合物是代谢稳定化的复合。此外，本发明涉及用于鉴定代谢稳定化合物的方法，其包括：a）使候选化合物与GPR43接触，和b）确定GPR43功能性是否增加，其中GPR43功能性的增加指示候选化合物为一种代谢稳定化合物。此外，本发明涉及鉴定代谢稳定化合物的方法，其包括：a）使候选化合物与GPR43接触，和b）确定GPR43功能性是否降低，其中GPR43功能性的降低指示候选化合物为代谢稳定化合物。

9. 发明申请

WO02068600A2 ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G PROTEIN-COUPLED RECEPTORS 审中-公开
标题翻译：人G蛋白偶联受体的内源性和非内源性版本
公开(公告)号：WO02068600A2
公开(公告)日：2002-09-06
申请号：PCT/US0205625
申请日：2002-02-26
申请人： ARENA PHARM INC , LIAW CHEN W , CHALMERS DEREK T , BEHAN DOMINIC P , MACIEJEWSKI-LENIOR DOMINIQUE , LEONARD JAMES N , LIN I-LIN , ORTUNO DANIEL
发明人： LIAW CHEN W , CHALMERS DEREK T , BEHAN DOMINIC P , MACIEJEWSKI-LENIOR DOMINIQUE , LEONARD JAMES N , LIN I-LIN , ORTUNO DANIEL
IPC分类号： C12N15/09 , C07K14/705 , C07K14/72 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N
CPC分类号： C07K14/705
摘要： The invention disclosed in this patent docuemnt relates to transmembrane receptors, more particularly to a human G protein-coupled receptor and to mutated (non-endogenous) versions of the human GPCRs for evidence activity.
摘要翻译：本专利文献中公开的发明涉及跨膜受体，更具体地涉及人G蛋白偶联受体和用于证据活性的人GPCR的突变（非内源）版本。

10. 发明申请

WO2006036688A9 GPR43 AND MODULATORS THEREOF FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS 审中-公开
标题翻译： GPR43及其与代谢相关性疾病治疗的调节剂
公开(公告)号：WO2006036688A9
公开(公告)日：2007-05-03
申请号：PCT/US2005033795
申请日：2005-09-21
申请人： ARENA PHARM INC , LEONARD JAMES N , HAKAK YARON
发明人： LEONARD JAMES N , HAKAK YARON
IPC分类号： G01N33/68
CPC分类号： G01N33/566 , G01N33/6845 , G01N2333/726 , G01N2500/00
摘要： The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.
摘要翻译：本发明涉及通过以下方式鉴定代谢稳定化合物的方法：a）使候选化合物与GPR43接触，和b）确定是否调节GPR43功能性，其中GPR43功能性的调节指示候选化合物是代谢稳定剂复合。此外，本发明涉及用于鉴定代谢稳定化合物的方法，其包括：a）使候选化合物与GPR43接触，和b）确定GPR43的功能是否增加，其中GPR43功能的增加指示候选化合物为代谢稳定化合物。此外，本发明涉及用于鉴定代谢稳定化合物的方法，包括：a）使候选化合物与GPR43接触，以及b）确定GPR43的功能性是否降低，其中GPR43功能的降低指示候选化合物为代谢稳定化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式